Back to top

Search

Cranberry A-type Proanthocyanidins Selectively Target Acute Myeloid Leukemia Cells

Posted: 
March 20, 2020
Authors: 
Laura M. Bystrom , Daniel P. Bezerra , Hsiao-Ting Hsu , Hongliang Zong , Luis A. Lara-Martínez , Jeanne P. De Leon , Megan Emmanuel , David Méry , Sara Gardenghi , Duane Hassane , Catherine C. Neto , Susanna Cunningham-Rundles , Michael W. Becker , Stefan
Journal: 
Blood Adv (2019) 3 (21): 3261–3265. https://doi.org/10.1182/bloodadvances.2018026633
Abstract: 

Most elderly patients affected with acute myeloid leukemia (AML) will relapse and die of their disease even after achieving complete remission, thus emphasizing the urgent need for new therapeutic approaches with minimum toxicity to normal hematopoietic cells. Cranberry (Vaccinium spp.) extracts have exhibited anticancer and chemopreventive properties that have been mostly attributed to A-type proanthocyanidin (A-PAC) compounds. A-PACs, isolated from a commercially available cranberry extract, were evaluated for their effects on leukemia cell lines, primary AML samples, and normal CD34+ cord blood specimens. Our results indicated potent and specific antileukemia activity in vitro. In addition, the antileukemia activity of A-PACs extended to malignant progenitor and stem cell populations, sparing their normal counterparts. The antileukemia effects of A-PACs were also observed in vivo using patient derived xenografts. Surprisingly, we found that the mechanism of cell death was driven by activation of NF-κB. Overall, our data suggest that A-PACs could be used to improve treatments for AML by targeting leukemia stem cells through a potentially novel pathway.